We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00301483
Recruitment Status : Unknown
Verified February 2008 by Biopure Corporation.
Recruitment status was:  Recruiting
First Posted : March 13, 2006
Last Update Posted : March 6, 2008
Information provided by:
Biopure Corporation

Brief Summary:
The main purpose of this study is to determine if HBOC-201 is safe and tolerable to trauma subjects, when given to treat the inadequate supply of blood and nutrients to tissues and organs.

Condition or disease Intervention/treatment Phase
Wounds and Injuries Drug: Hemoglobin-based oxygen carrier-201 (HBOC 201) Other: Standard of Care Phase 2

Detailed Description:

This Phase II study will be a single-center, randomized, single-blind, parallel-group, standard therapy-controlled, variable dose study of HBOC 201 administered to trauma subjects with bleeding or potential for bleeding who require standard fluid therapy for treatment of hypoperfusion. The type and incidence of adverse events and serious adverse events attributed to the study drug will be analyzed.

Secondary variables in this safety and tolerability study, will be summarized with descriptive statistics and frequency tables. The purpose of this data collection is to assess efficacy variables and the feasibility of utilizing these parameters in future trauma studies that will assess parameters of morbidity and mortality and include, but are not limited to:

  • Time to improvement of serum (or plasma) lactate
  • Time to improvement in the Base Deficit
  • Time to maintained stability (BD<5) over 24 hours
  • Overall improvement in Base Deficit over 24 Hours
  • Stability of subjects at 24 hours
  • Time to meet treatment-stopping criteria
  • Volume to meet treatment-stopping criteria
  • Incidence of infectious complications (e.g., incidence of ventilator-associated pneumonia)
  • Length of time on ventilator
  • Incidence of multiple organ dysfunction (MOD)

Hemorrhage with subsequent hypoperfusion is a major cause of both immediate and delayed death in subjects who have sustained traumatic injuries. Effective therapies for hemorrhage to treat hypoperfusion that can be given immediately following injury are lacking. The following issues confound this problem further:

  • Hemorrhaging trauma victims often have an immediate need for therapy to ensure adequate delivery of oxygen to vital tissues;
  • Standard of care fluids such as Lactated Ringers Solution do not provide oxygen and blood can not be readily stored, transported or easily used in pre-hospital settings
  • In the absence of oxygen-carrying fluid, traditional approaches to sustain vital organ perfusion, such as administration of intravenous fluid therapy, may have detrimental effects if given prior to hemostasis in certain subjects, particularly those with penetrating truncal injuries.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Single-Center, Study to Evaluate the Safety and Tolerability of Hemoglobin-Based Oxygen Carrier-201 (HBOC 201) in Trauma Subjects. (Phase II - Safety and Tolerability)
Study Start Date : July 2004
Estimated Primary Completion Date : September 2008
Estimated Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
HBOC-201 followed by standard therapy
Drug: Hemoglobin-based oxygen carrier-201 (HBOC 201)
HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
Active Comparator: 2
Standard Therapy
Other: Standard of Care
Standard Therapy

Primary Outcome Measures :
  1. Safety/Tolerability of HBOC-201 for treatment of hypoperfusion in trauma by analysis of AEs/SAEs attributed to study drug [ Time Frame: Duration of the study (Randomization through 28-day follow-up) ]

Secondary Outcome Measures :
  1. Efficacy/feasibility of the following measurements in trauma studies (list is not all inclusive): Time to serum lactate improvement, Base deficit (BD) improvement, BD > 5 over 24 hrs, 24 hr stability, Infection, Vent time [ Time Frame: Duration of the study (Randomization through 28-day follow-up) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Male or Female (females not of childbearing potential or negative pregnancy test prior to enrollment)
  • Age ≥ 18 years and ≤ 65 years of age
  • Trauma with bleeding or a potential for bleeding arriving at initial treatment facility directly from scene of injury
  • Subject should be enrolled within four (4) hours of injury
  • Base Deficit (BD) greater than 5.0 and one of the following:

Systolic Blood Pressure ≤ 100 mm Hg OR Sustained (≥ 10 minutes) Heart Rate ≥ 100

  • No localized signs of traumatic brain injury and a Glasgow Coma Score of ≥9 with the exception of drug-induced lowered GCS.
  • Informed consent, or independent physician authorization obtained


  • Known or suspected Traumatic Brain Injury
  • Non-survivable injury (Falcone Criteria)
  • Traumatic arrest
  • Known prior cardiac arrest (i.e., preceding trauma episode)
  • Known or suspected pregnancy
  • Known allergy to bovine products
  • Prior treatment with blood (subsequent to current trauma)
  • Informed consent or independent physician authorization unable to be obtained
  • Unable to meet protocol or follow-up criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00301483

Contact: Tiana Gorham tgorham@biopure.com

South Africa
Department of Surgery: Johannesburg Hospital Recruiting
Johannesburg, Gauteng, South Africa
Contact: Ronel Snyman    011 488 3943    research.jhb@mweb.co.za   
Principal Investigator: Professor Ken D Boffard, MD         
Sponsors and Collaborators
Biopure Corporation
Study Director: A. Gerson Greenburg, MD, PhD Biopure Corporation
Principal Investigator: Professor Ken D Boffard, MD Wits University Medical School

Responsible Party: Biopurure Corporation, Biopure
ClinicalTrials.gov Identifier: NCT00301483     History of Changes
Other Study ID Numbers: HEM-0125
First Posted: March 13, 2006    Key Record Dates
Last Update Posted: March 6, 2008
Last Verified: February 2008

Keywords provided by Biopure Corporation:
multiple trauma
bleeding injuries
gunshot wounds
stab wounds
penetrating injuries
blunt trauma
multiple wounds

Additional relevant MeSH terms:
Wounds and Injuries
HBOC 201
Blood Substitutes